Using molecular technology and computational virtual screening, Orpha Biotech creates small-molecule medications for orphan diseases. Their focus is on developing solutions for diseases that have a low occurrence rate and lack effective therapies. By employing structure-based computational virtual screening and docking simulations, they identify potential agonists or antagonists for the treatment of juvenile rheumatoid arthritis and cutaneous systemic sclerosis. Orpha Biotech aims to address the unmet medical needs of patients with rare diseases through their pharmaceutical drug development.